Compare NCNO & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NCNO | MIRM |
|---|---|---|
| Founded | 2011 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.7B |
| IPO Year | 2020 | 2019 |
| Metric | NCNO | MIRM |
|---|---|---|
| Price | $23.38 | $68.49 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 11 |
| Target Price | $33.40 | ★ $82.82 |
| AVG Volume (30 Days) | ★ 2.2M | 549.3K |
| Earning Date | 12-03-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $586,485,000.00 | $471,794,000.00 |
| Revenue This Year | $10.88 | $53.78 |
| Revenue Next Year | $8.53 | $19.91 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 12.14 | ★ 53.66 |
| 52 Week Low | $18.75 | $36.88 |
| 52 Week High | $40.29 | $78.55 |
| Indicator | NCNO | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 35.75 | 44.02 |
| Support Level | $24.12 | $68.60 |
| Resistance Level | $27.50 | $71.98 |
| Average True Range (ATR) | 0.98 | 2.55 |
| MACD | -0.03 | -0.09 |
| Stochastic Oscillator | 0.93 | 7.55 |
Ncino Inc is a provider of cloud-based software for financial institutions. Its software solution digitizes, automates, and streamlines inefficient and complex processes & workflows and utilizes data analytics & artificial intelligence that enables financial institutions to onboard new clients, make loans, and manage the entire loan life cycle, open deposits, and other accounts, and manage regulatory compliance. It also offers professional services, including configuration & implementation, training, and advisory services. The company generates the majority of its revenue from subscription services. The company caters to financial institutions, enterprise banks, regional banks, community banks, and credit unions. The vast majority of its revenue comes from the United States.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.